These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 12866028)
21. IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice. Di Carlo E; Comes A; Orengo AM; Rosso O; Meazza R; Musiani P; Colombo MP; Ferrini S J Immunol; 2004 Feb; 172(3):1540-7. PubMed ID: 14734732 [TBL] [Abstract][Full Text] [Related]
22. Interleukin-12 gene modification exerts anti-tumor effects on murine mammary sarcoma cell line in vivo. Li D; Yu H; Xu TF; Li JH; Sun YF; Zhang WQ Cell Mol Immunol; 2008 Jun; 5(3):225-30. PubMed ID: 18582405 [TBL] [Abstract][Full Text] [Related]
23. Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Schaider H; Oka M; Bogenrieder T; Nesbit M; Satyamoorthy K; Berking C; Matsushima K; Herlyn M Int J Cancer; 2003 Jan; 103(3):335-43. PubMed ID: 12471616 [TBL] [Abstract][Full Text] [Related]
24. Gene transfer of secreted-type modified interleukin-18 gene to B16F10 melanoma cells suppresses in vivo tumor growth through inhibition of tumor vessel formation. Nagai H; Hara I; Horikawa T; Oka M; Kamidono S; Ichihashi M J Invest Dermatol; 2002 Sep; 119(3):541-8. PubMed ID: 12230493 [TBL] [Abstract][Full Text] [Related]
25. Immunotherapy with interleukin-10 depends on the CXC chemokines inducible protein-10 and monokine induced by IFN-gamma. Dorsey R; Kundu N; Yang Q; Tannenbaum CS; Sun H; Hamilton TA; Fulton AM Cancer Res; 2002 May; 62(9):2606-10. PubMed ID: 11980656 [TBL] [Abstract][Full Text] [Related]
26. Interferon gamma (IFNgamma) gene transfer of an EMT6 tumor that is poorly responsive to IFNgamma stimulation: increase in tumor immunogenicity is accompanied by induction of a mouse class II transactivator and class II MHC. Panelli MC; Wang E; Shen S; Schluter SF; Bernstein RM; Hersh EM; Stopeck A; Gangavalli R; Barber J; Jolly D; Akporiaye ET Cancer Immunol Immunother; 1996 Feb; 42(2):99-107. PubMed ID: 8620527 [TBL] [Abstract][Full Text] [Related]
27. Constitutive upregulation of hypoxia-inducible factor-1alpha mRNA occurring in highly metastatic lung carcinoma cells leads to vascular endothelial growth factor overexpression upon hypoxic exposure. Koshikawa N; Iyozumi A; Gassmann M; Takenaga K Oncogene; 2003 Oct; 22(43):6717-24. PubMed ID: 14555985 [TBL] [Abstract][Full Text] [Related]
28. T lymphocytes infiltrating sites of tumor rejection and progression display identical V beta usage but different cytotoxic activities. Kurt RA; Park JA; Panelli MC; Schluter SF; Marchalonis JJ; Carolus B; Akporiaye ET J Immunol; 1995 Apr; 154(8):3969-74. PubMed ID: 7706735 [TBL] [Abstract][Full Text] [Related]
29. Treatment of established tumor is associated with ICAM-1 upregulation and reversed by CD8 depletion in a tumor necrosis factor-alpha gene transfected mouse mammary tumor. Matory YL; Dorfman DM; Wu L; Chen M; Goedegebuure P; Eberlein TJ Pathobiology; 1999; 67(4):186-95. PubMed ID: 10738180 [TBL] [Abstract][Full Text] [Related]
31. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Wei LH; Kuo ML; Chen CA; Chou CH; Lai KB; Lee CN; Hsieh CY Oncogene; 2003 Mar; 22(10):1517-27. PubMed ID: 12629515 [TBL] [Abstract][Full Text] [Related]
32. IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms. Sorensen EW; Gerber SA; Frelinger JG; Lord EM J Immunol; 2010 Feb; 184(4):1858-66. PubMed ID: 20061409 [TBL] [Abstract][Full Text] [Related]
33. Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapy. Gorczynski RM; Chen Z; Erin N; Khatri I; Podnos A PLoS One; 2014; 9(11):e113597. PubMed ID: 25409195 [TBL] [Abstract][Full Text] [Related]
34. Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas. Ding I; Sun JZ; Fenton B; Liu WM; Kimsely P; Okunieff P; Min W Cancer Res; 2001 Jan; 61(2):526-31. PubMed ID: 11212245 [TBL] [Abstract][Full Text] [Related]
35. Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy. Ahn HM; Hong J; Yun CO Oncotarget; 2016 Dec; 7(51):84965-84980. PubMed ID: 27821803 [TBL] [Abstract][Full Text] [Related]
36. Expression of the chemokines IP-10 and Mig in IL-10 transduced tumors. Sun H; Kundu N; Dorsey R; Jackson MJ; Fulton AM J Immunother; 2001; 24(2):138-43. PubMed ID: 11265771 [TBL] [Abstract][Full Text] [Related]
37. In vivo activities of mutants of vascular endothelial growth factor (VEGF) with differential in vitro activities. Leenders W; van Altena M; Lubsen N; Ruiter D; De Waal R Int J Cancer; 2001 Feb; 91(3):327-33. PubMed ID: 11169955 [TBL] [Abstract][Full Text] [Related]
38. IL-12 regulates VEGF and MMPs in a murine breast cancer model. Dias S; Boyd R; Balkwill F Int J Cancer; 1998 Oct; 78(3):361-5. PubMed ID: 9766572 [TBL] [Abstract][Full Text] [Related]
39. Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer. Kohno T; Mizukami H; Suzuki M; Saga Y; Takei Y; Shimpo M; Matsushita T; Okada T; Hanazono Y; Kume A; Sato I; Ozawa K Cancer Res; 2003 Aug; 63(16):5091-4. PubMed ID: 12941839 [TBL] [Abstract][Full Text] [Related]
40. Interferon-gamma produced by interleukin-12-activated tumor infiltrating CD8+T cells directly induces apoptosis of mouse hepatocellular carcinoma. Komita H; Homma S; Saotome H; Zeniya M; Ohno T; Toda G J Hepatol; 2006 Nov; 45(5):662-72. PubMed ID: 16935390 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]